The drug is the first and only approved oral, controlled-release budesonide treatment for UC patients when mesalazine treatment is not sufficient.
The company also released new data from the CONTRIBUTE trial that showed that adding CORTIMENTMMX 9 mg was significantly more effective than placebo at inducing combined clinical and endoscopic remission in UC patients experiencing a flare up despite oral mesalazine therapy.
More articles on GI/endoscopy:
7 things for gastroenterologists to know for today
GI/endoscopy company stock report – Feb. 20, 2015
What gastroenterologists can expect from a physician shortage
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
